Sign in
Active, not recruitingNo phase

Assessment of DOT Spectacles in Chinese Children

Key facts

Who runs it
SightGlass Vision, Inc.
Where
China5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
195 people enrolled
Started
5 Feb 2023
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Novel spectacle lens design
  • Spectacle lenses
Record updated
13 July 2026

Who can take part

Age
6 years to 13 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Children 6-13 years of age
  • SER error between -0.75D and -5.00D
  • Willingness to wear study spectacles and participate in the trial for 12 months without contact lens wear

Who cannot take part

  • Prior usage of atropine, multifocal contact lenses, or orthokeratology (ortho-K)
  • Astigmatism worse than -1.50 DC (by manifest refraction) in either eye
  • Anisometropia (SER manifest refraction) greater than 1.00 D

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized, controlled, evaluator-blinded, multicenter, two-arm parallel group clinical trial to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses by comparing to single vision, impact-resistant spectacle lenses in reducing the progression of myopia in children of Chinese origin.

The 2 groups in the trial

  • SightGlass Vision Test Arm 1Treatment being tested

    Single vision, impact-resistant spectacle lenses

    Treatment: Novel spectacle lens design

  • Test Arm 2Other group

    Single vision, impact-resistant spectacle lenses

    Treatment: Spectacle lenses

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Assessment of DOT Spectacle Lenses in Chinese Children
Record updated
13 July 2026